Real-world study of IBI-351 for KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well the drug IBI-351 works in real-world settings for people with advanced lung cancer that has a specific genetic change (KRAS G12C). It helps doctors understand how the drug performs outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that has spread to nearby tissues or other parts of your body.
- A genetic test shows your tumor has a specific change called KRAS G12C.
- You took the study drug IBI-351 at least once between August 2024 and August 2025.
- You agree to take part in the study and sign a consent form.
- Your tumor is not mostly small cell or squamous cell carcinoma.
- You do not have other gene changes like EGFR, ALK, or ROS1 that already have standard treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
This trial tests a new combination of two targeted drugs (Fulzerasib and Ivonescimab) as a first treatment for advanced or metastatic lung cancer that has a specific KRAS G12C mutation. The goal is to see if this treatment works well and is safe.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.